Making big drugs during troubled times: The Amgen Experience
Investor Relations - Monday, March 8, 2010 - 1 Comment
These are momentous times for Amgen, which is the world’s largest biotech company. The health-care revolution brewing in Washington could be dramatically good news or bad for a business whose drugs tend to be life-changing—and highly expensive.
Also on deck this year is a critical FDA decision on Amgen’s Denosumab, a possible blockbuster treatment for osteoporosis and bone cancer on which Amgen is betting heavily. If it’s approved, analysts expect annual sales of at least $1 billion—maybe double or triple that. Overseeing it all is CEO Kevin Sharer, 61, who joined the company 17 years ago as a newcomer to biotech after a career with the U.S. Navy, McKinsey, General Electric, among others. >>>
- The good company: Capitalism and ethics
- Test post
- Kanadariya Energy may suffer losses over Chesapeake Oil Well Accidents
- Customer Service is at the Center of what we do
- Chem Analytica may raise up to $100M in Rights Offering
- UBA Earnings May Increase on Investment Banking Fees
- Regional Expansion is central to Skye Bank Strategy
Most comments
- Kanadariya Energy may suffer losses over Chesapeake Oil Well Accidents - July 30, 2009 (4)
- Chem Analytica may raise up to $100M in Rights Offering - June 24, 2009 (1)
- The good company: Capitalism and ethics - March 02, 2010 (1)
- Making big drugs during troubled times: The Amgen Experience - March 08, 2010 (1)
- UBA Earnings May Increase on Investment Banking Fees - May 03, 2009 (0)
Most read
- No results available
What I'm Doing...
- The world has never been ready for a challenger brand. It never will be. 2010-03-02
- No economy or market can be truly successful without a vibrant business and financial news providers' network. 2010-03-02
- Valueclear Journal has set ambitious targets. The most important: to inform the reader. 2010-03-02
- The financial press in Nigeria needs to re-examine itself. Has it lived up to expectations? If not, why? 2010-03-02
- Business news should be, first and foremost, about analysis. Descriptive narrative comes a distant second. 2010-03-02
- For economy, business and financial news on companies on the Nigerian Stock Exchange, Valueclear Journal goes beyond. Then some. 2010-03-02
- Savvy readers of business media expect to be informed about not only the 'what' happened, but the 'why' and 'how'. 2010-03-02
- Investors want more than fleeting coverage of the breaking news. They want news content that is well-researched, readable and informative. 2010-03-02
- Valueclear Journal provides in-depth analysis on business, markets and the economy. 2010-03-02
- Valueclear is an online investor relations platform serving companies on the Nigerian Stock Exchange. 2010-03-01
- More updates...
Posting tweet...
Powered by Twitter Tools
